HCA Healthcare (HCA) Stock May Be 49% Undervalued As Wage Pressure Builds
HCA Healthcare stock has produced a 75.1% return over the past five years, yet current valuation checks suggest the shares may still trade at a discount to an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. At the same time, recent headlines around worker pay, staffing, leadership changes and new urgent care acquisitions give investors more to weigh as they think about what that valuation gap really reflects.
- A 75.1% return over five years signals that HCA Healthcare has already rewarded long term holders. Any further upside case now rests on whether cash flows can support more value from here.
- Planned leadership changes in clinical roles and the expansion of urgent care in Texas may support future cash generation. Union pressure for higher wages and more staffing could add cost risk that affects margins and valuation.
- HCA Healthcare screens as undervalued on most of Simply Wall St's broader checks, with a 5 out of 6 value score that lines up with a Discounted Cash Flow (DCF) estimate suggesting the stock may trade around 48.9% below intrinsic value.
The issue now is whether the current share price already reflects these operational risks or if the Discounted Cash Flow (DCF) and market multiples are pointing to a margin of safety that may still be in investors' favor.
Find out why HCA Healthcare's 6.1% return over the last year is lagging behind its peers.
Does HCA Healthcare Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what HCA Healthcare’s future cash generation could be worth in today’s dollars. The company has reported latest twelve month free cash flow of about $6.0b, and the DCF framework assumes these cash flows continue growing rather than shrinking. On that basis, the model arrives at an estimated intrinsic value of around $804 per share.
Compared with the current share price, this implies HCA Healthcare screens as about 48.9% undervalued on this cash flow view. The recent push by union workers for higher pay and staffing helps explain why the market might discount those cash flows, since higher labor costs could pressure future margins. Even so, the DCF output suggests that, after factoring in these projected cash flows, the share price sits well below the model’s estimate of underlying value.
Overall, the Discounted Cash Flow (DCF) workup indicates HCA Healthcare stock appears undervalued relative to the cash the business is projected to generate.
Our Discounted Cash Flow (DCF) analysis suggests HCA Healthcare is undervalued by 48.9%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.
Is HCA Healthcare a Bargain on Earnings?
P/E is a useful cross check for HCA Healthcare because earnings are a key driver of how hospital operators are priced. On this measure, HCA Healthcare currently trades on a P/E of about 13.0x. That sits below the healthcare industry average of about 24.7x and also below the peer group average of roughly 16.0x.
A more tailored “fair” multiple for HCA Healthcare, which takes account of its size, sector, margins and risk profile, comes out at about 26.8x. This is roughly double the current P/E, which indicates that the stock is changing hands at a discount to what this framework suggests could be a reasonable level for its earnings. The gap exists even as investors consider issues such as union pay demands, staffing costs and the integration of the new Texas urgent care assets into the broader business.
On a P/E basis, HCA Healthcare stock appears undervalued compared with both the wider healthcare sector and its own modelled fair multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The HCA Healthcare Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for HCA Healthcare aim to connect the valuation gap you have just seen with the specific stories that could explain it. Each Narrative sets out what would need to happen to HCA Healthcare's growth, margins and earnings for the stock to be worth meaningfully more or less than today's price, and links that to a single fair value tied to defined catalysts and risks so you can see which version of events is gradually playing out. These are available on Simply Wall St's Community page and give you structured scenarios to compare against real world developments over time.
Community views on HCA Healthcare sit far apart, with one camp focused on scale and resilience and the other on cost and execution risk.
Bull case: 35% undervalued
"With hospitals, surgery centers, and outpatient facilities spread across the U.S., the company benefits from scale in ways smaller providers simply can’t match…"
Read the full Bull Case to see why HCA Healthcare could be undervalued
Bear case: roughly fairly valued
"Digital programs and an AI agenda are being rolled out across more facilities, and the upfront spend on technology, professional fees and support functions is already reflected in higher other operating expenses…"
Read the full Bear Case to see why HCA Healthcare could be overvalued
Do you think there's more to the story for HCA Healthcare? Head over to our Community to see what others are saying!
The Bottom Line
HCA Healthcare screens as undervalued on both Discounted Cash Flow (DCF) and P/E based earnings checks, which point in the same direction and are backed by a strong overall value assessment. That sets up a clear question for you as an investor. The key issue is whether staffing, wage pressure and the cost of integrating new facilities ultimately erode the cash generation that supports the intrinsic value estimate. The crux of the bull versus bear debate is whether HCA Healthcare can protect margins enough for that current discount to be an opportunity rather than a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com